Research programme: bone marrow transplant therapeutics - CellCyte GeneticsAlternative Names: CCG-T50; Stem cell therapeutics - CellCyte Genetics
Latest Information Update: 16 Jul 2016
At a glance
- Originator Department of Veterans Affairs
- Mechanism of Action Cell replacements
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Bone marrow disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Bone-marrow-disorders in USA (Parenteral)
- 01 Oct 2005 Preclinical trials in Bone marrow disorders in USA (Parenteral)